Drug Trial Radar · NCT06265025
GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Mar 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
125
Planned (sponsor's estimate)
Start
Feb 20, 2024
Primary completion
May 30, 2025
Study completion Oct 30, 2028
Sponsor
- Lead sponsor
- GeneMedicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 20, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to measure safety, tolerability, and preliminary antitumor efficacy of GM103 administered alone and in combination with pembrolizumab in patients with locally advanced, unresectable, refractory and/or metastatic solid tumors (including but not limited to head and neck cancer, malignant melanoma, CRC, renal cell carcinoma, cervical cancer, and breast cancer). Study details include:
Conditions
- Head and Neck Cancer
- Malignant Melanoma
- Colorectal Cancer
- Renal Cell Carcinoma
- Cervical Cancer
- Breast Cancer
Interventions
GM103 (Part A)Drug
dose escalation of GM103 as monotherapy, conducted in 12-24 patients. Part A will include a screening period of up to 28 days, a dose limiting toxicity (DLT) evaluation period of the first 2 cycles, and a treatment period from cycles 3-12 (each cycle will consist of 14 days \[2 weeks\]).
GM103 (Part B)Drug
dose expansion study of GM103 as monotherapy, conducted in up to 40 patients (a minimum of 20 patients per target disease \[HNC, CRC\]). Part B of the study will include a screening period of up to 28 days, and 1 to a maximum of 12 treatment cycles (each cycle will consist of 14 days \[2 weeks\]).
GM103 and Pembrolizumab (Part C)Drug
dose-escalation and dose-expansion of GM103 in combination with pembrolizumab, conducted in approximately 61 patients. Part C of the study will include a screening period of up to 28 days, a safety run-in period of 2 cycles (it consists of 2 cohorts and the first 1 cycle for the DLT assessment period of each cohort is included, each cycle will consist of 21 days \[3 weeks\]), and a dose expansion period from cycle 3 to a maximum of 12 treatment cycles (of 21 days \[3 weeks\]).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of patients with DLTs by cohortsTime frame: during the first 28 days of treatment
- Percentage of patients with DLTsTime frame: during the first 21 days of treatment
- Incidence of AEs, AESIs, SAEs, AEs leading to discontinuation, and AEs resulting in deathTime frame: through study completion, and average 1 year
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Korea University Anam Hospital
Seoul, South Korea · Not yet recruiting
Hanyang University Seoul Hospital
Seoul, South Korea · Not yet recruiting
Severance Hospital, Yonsei University Health System
Seoul, South Korea · Recruiting
National Cancer Center
Goyang-si, Gyeonggi-do, South Korea · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.